Centers for Disease Control and Prevention. Interim guidance on evaluating and caring for patients with post-COVID conditions. Accessed October 11, 2022. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-index.html
Nath A. Long-haul COVID. Neurology. 2020;95(13):559-560.
Greenhalgh T, Knight M, A’Court C, et al. Management of post-acute COVID-19 in primary care. BMJ. 2020;370:m3026.
Logue JK, Franko NM, McCulloch DJ, et al. Sequelae in adults at 6 months after COVID-19 infection [published correction appears in JAMA Netw Open. 2021; 4(3): e214572]. JAMA Netw Open. 2021;4(2):e210830.
Centers for Disease Control and Prevention. Nearly one in five American adults who have had COVID-19 still have “long COVID.” Accessed October 4, 2022. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm
- Zimmermann P, Pittet LF, Curtis N. How common is long COVID in children and adolescents? Pediatr Infect Dis J. 2021;40(12):e482-e487.
Datta SD, Talwar A, Lee JT. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: illness beyond acute infection and public health implications. JAMA. 2020;324(22):2251-2252.
Darby JB, Jackson JM. Kawasaki disease and multisystem inflammatory syndrome in children: an overview and comparison. Am Fam Physician. 2021;104(3):244-252.
Payne AB, Gilani Z, Godfred-Cato S, et al. Incidence of multisystem inflammatory syndrome in children among US persons infected with SARS-CoV-2. JAMA Netw Open. 2021;4(6):e2116420.
Centers for Disease Control and Prevention. Infectious Diseases Society of America. Multisystem inflammatory syndrome in adults (MIS-A). Updated June 24, 2022. Accessed August 31, 2022. https://www.idsociety.org/covid-19-real-time-learning-network/disease-manifestations--complications/multisystem-inflammatory-syndrome-in-adults-mis-a/
Su Y, Yuan D, Chen DG, et al.; ISB-Swedish COVID-19 Biobanking Unit. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881-895.e20.
Tenforde MW, Kim SS, Lindsell CJ, et al.; IVY Network Investigators; CDC COVID-19 Response Team. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network – United States, March–June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(30):993-998.
Aiyegbusi OL, Hughes SE, Turner G, et al.; TLC Study Group. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021;114(9):428-442.
Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22(1):43-55.
Crook H, Raza S, Nowell J, et al. Long COVID-mechanisms, risk factors, and management [published correction appears in BMJ. 2021; 374: n1944]. BMJ. 2021;374:n1648.
Kamal M, Abo Omirah M, Hussein A, et al. Assessment and characterisation of post-COVID-19 manifestations. Int J Clin Pract. 2021;75(3):e13746.
Sneller MC, Liang CJ, Marques AR, et al. A longitudinal study of COVID-19 sequelae and immunity: baseline findings. Ann Intern Med. 2022;175(7):969-979.
Centers for Disease Control and Prevention. Long COVID or post-COVID conditions. Updated September 1, 2022. Accessed October 1 1, 2022. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html
World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus. Updated October 6, 2021. Accessed August 31, 2022. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1
Herrera JE, Niehaus WN, Whiteson J, et al. Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of fatigue in postacute sequelae of SARS-CoV-2 infection (PASC) patients [published correction appears in PM R. 2022; 14(1): 164]. PM R. 2021;13(9):1027-1043.
Petersen LR, Sami S, Vuong N, et al. Lack of antibodies to severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) in a large cohort of previously infected persons. Clin Infect Dis. 2021;73(9):e3066-e3073.
Greenhalgh T, Knight M. Long COVID: a primer for family physicians. Am Fam Physician. 2020;102(12):716-717.
Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EclinicalMedicine. 2021;38:101019.
Vance H, Maslach A, Stoneman E, et al. Addressing post-COVID symptoms: a guide for primary care physicians. J Am Board Fam Med. 2021;34(6):1229-1242.
Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6(9):e005427.
Han Q, Zheng B, Daines L, et al. Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens. 2022;11(2):269.
Alkodaymi MS, Omrani OA, Fawzy NA, et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(5):657-666.
Décary S, Gaboury I, Poirier S, et al. Humility and acceptance: working within our limits with long COVID and myalgic encephalomyelitis/chronic fatigue syndrome. J Orthop Sports Phys Ther. 2021;51(5):197-200.
Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; Board on the Health of Select Populations; Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. National Academies Press; 2015.
Larsen NW, Stiles LE, Miglis MG. Preparing for the long-haul: autonomic complications of COVID-19. Auton Neurosci. 2021;235:102841.
Dani M, Dirksen A, Taraborrelli P, et al. Autonomic dysfunction in ‘long COVID’: rationale, physiology and management strategies. Clin Med (Lond). 2021;21(1):e63-e67.
Dysautonomia International. Postural orthostatic tachycardia syndrome. 2019. Accessed March 2, 2022. http://www.dysautonomiainternational.org/page.php?ID=30
Cheng A, Shih E, Gupta N, et al.; OHSU Long COVID-19 Clinical Guidelines Team. Long COVID clinical guidelines. April 2021. Updated September 9, 2021. Accessed March 2, 2022. https://rise.articulate.com/share/7Z5i0jOWRACIdVf3LlOMb4HCT6Ed8RIc#/
Sheldon RS, Grubb BP II, Olshansky B, et al. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12(6):e41-e63.
Fu Q, Levine BD. Exercise and non-pharmacological treatment of POTS. Auton Neurosci. 2018;215:20-27.
Garland EM, Raj SR. Differential diagnosis of vasovagal syncope: postural orthostatic tachycardia. Vasovagal Syncope. 2014:179-188.
Kohno R, Cannom DS, Olshansky B, et al. Mast cell activation disorder and postural orthostatic tachycardia syndrome: a clinical association. J Am Heart Assoc. 2021;10(17):e021002.
Fine JS, Ambrose AF, Didehbani N, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cognitive symptoms in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022;14(1):96-111.
Maley JH, Alba GA, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of breathing discomfort and respiratory sequelae in patients with post-acute sequelae of SARSCoV-2 infection (PASC). PM R. 2022;14(1):77-95.
Afrin LB, Weinstock LB, Molderings GJ. COVID-19 hyper-inflammation and post-COVID-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327-332.
Theoharides TC, Conti P. COVID-19 and multisystem inflammatory syndrome, or is it mast cell activation syndrome?. J Biol Regul Homeost Agents. 2020;34(5):1633-1636.
Molderings GJ, Brettner S, Homann J, et al. Mast cell activation disease. J Hematol Oncol. 2011;4:10.
Klok FA, Boon GJAM, Barco S, et al. The post-COVID-19 functional status scale: a tool to measure functional status over time after COVID-19. Eur Respir J. 2020;56(1):2001494.
Groff D, Sun A, Ssentongo AE, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4(10):e2128568.
Miller AJ, Raj SR. Pharmacotherapy for postural tachycardia syndrome. Auton Neurosci. 2018;215:28-36.
Berger Z, Altiery DE Jesus V, et al. Long COVID and health inequities: the role of primary care. Milbank Q. 2021;99(2):519-541.
U.S. Department of Health and Human Services. Guidance on “long COVID” as a disability under the ADA, section 504, and section 1557. July 26, 2021. Accessed August 31, 2022. https://www.hhs.gov/civil-rights/for-providers/civil-rights-COVID19/guidance-long-COVID-disability/index.html